Gene–gene and gene–environment interactions in apolipoprotein L1 gene-associated nephropathy

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 11, 2014, Pages 2006-2013

  Freedman, Barry I ^a   Skorecki, Karl ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Molecular Medicine Laboratory   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICAN AMERICAN; APOLIPOPROTEIN L1 GENE; ARTICLE; CELL DEATH; CHROMOSOME 22Q; CHRONIC KIDNEY DISEASE; END STAGE RENAL DISEASE; FOCAL GLOMERULOSCLEROSIS; GENE; GENE EXPRESSION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IMMUNOCOMPROMISED PATIENT; JC VIRUS; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; PROTEINURIA; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS INFECTION; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE COURSE; EPISTASIS; ETHNOLOGY; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; PATHOLOGY; VIROLOGY;

APOL1 PROTEIN, HUMAN; APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN;

AFRICAN AMERICANS; APOLIPOPROTEINS; DISEASE PROGRESSION; EPISTASIS, GENETIC; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HIV INFECTIONS; HUMANS; LIPOPROTEINS, HDL; RENAL INSUFFICIENCY, CHRONIC;

EID: 84923866989     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.01330214     Document Type: Article

References (73)

1. McClellan J, King MC: Genetic heterogeneity in human disease. Cell 141: 210–217, 2010
2. Manolio TA: Bringing genome-wide association findings into clinical use. Nat Rev Genet 14: 549–558, 2013
3. Hall SS: Revolution postponed. Sci Am 303: 60–67, 2010
4. Todd JA: D’oh! genes and environment cause Crohn’s disease. Cell 141: 1114–1116, 2010
5. Virgin HW, Wherry EJ, Ahmed R: Redefining chronic viral infection. Cell 138: 30–50, 2009
6. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY, Yang CW: Chronic kidney disease: Global dimension and perspectives. Lancet 382: 260–272, 2013
7. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329: 841–845, 2010
8. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, Wasser WG, Behar DM, Skorecki K: Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128: 345–350, 2010
9. US Renal Data System: USRDS 2012 Annual Data Report, Vol 1: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012
10. Muntner P, Newsome B, Kramer H, Peralta CA, Kim Y, Jacobs DR Jr., Kiefe CI, Lewis CE: Racial differences in the incidence of chronic kidney disease. Clin J AmSoc Nephrol 7: 101–107, 2012
11. Freedman BI, Kopp JB, Langefeld CD, Genovese G, Friedman DJ, Nelson GW, Winkler CA, Bowden DW, Pollak MR: The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 21: 1422–1426, 2010
12. Hall YN, Choi AI, Xu P, O’Hare AM, Chertow GM: Racial ethnic differences in rates and determinants of deceased donor kidney transplantation. J Am Soc Nephrol 22: 743–751, 2011
13. Chakkera HA, O’Hare AM, Johansen KL, Hynes D, Stroupe K, Colin PM, Chertow GM: Influence of race on kidney transplant outcomes within and outside the Department of Veterans Affairs. J Am Soc Nephrol 16: 269–277, 2005
14. Callender CO, Cherikh WS, Traverso P, Hernandez A, Oyetunji T, Chang D: Effect of donor ethnicity on kidney survival in different recipient pairs: An analysis of the OPTN/UNOS database. Transplant Proc 41: 4125–4130, 2009
15. Rosset S, Tzur S, Behar DM, Wasser WG, Skorecki K: The population genetics of chronic kidney disease: Insights from the MYH9-APOL1 locus. Nat Rev Nephrol 7: 313–326, 2011
16. Friedman DJ, Pollak MR: Genetics of kidney failure and the evolving story of APOL1. J Clin Invest 121: 3367–3374, 2011
17. Genovese G, Friedman DJ, Pollak MR: APOL1 variants and kidney disease in people of recent African ancestry. Nat Rev Nephrol 9: 240–244, 2013
18. Pollak MR, Genovese G, Friedman DJ: APOL1 and kidney disease. Curr Opin Nephrol Hypertens 21: 179–182, 2012
19. Freedman BI, Langefeld CD: The new era of APOL1-associated glomerulosclerosis. NephrolDial Transplant 27: 1288–1291, 2012
20. Wasser WG, Tzur S, Wolday D, Adu D, Baumstein D, Rosset S, Skorecki K: Population genetics of chronic kidney disease: The evolving story of APOL1. J Nephrol 25: 603–618, 2012
21. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA: APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 22: 2129–2137, 2011
22. Ashley-Koch AE, Okocha EC, Garrett ME, Soldano K, De Castro LM, Jonassaint JC, Orringer EP, Eckman JR, Telen MJ: MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol 155: 386–394, 2011
23. Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, Astor BC, Bottinger EP, Iyengar SK, Klotman PE, Freedman RG, Zhang W, Parekh RS, Choi MJ, Nelson GW, Winkler CA, Kopp JB; SK Investigators: Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 83: 114–120, 2013
24. Larsen CP, Beggs ML, Saeed M, Walker PD: Apolipoprotein L1 risk variants associate with systemic lupus erythematosusassociated collapsing glomerulopathy. J Am Soc Nephrol 24: 722–725, 2013
25. Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, Birmingham DJ, Hebert LA, Hicks PJ, Segal MS, Edberg JC, Brown EE, Costenbader KH, Comeau ME, Criswell LA, Harley JB, James JA, Kamen DL, Lim SS, Merrill JT, Sivils KM, Niewold TB, Patel NM, Petri M, Ramsey-Goldman R, Reveille JD, Salmon JE, Tsao BP, Gibson KL, Byers JR, Vinnikova AK, Lea JP, Julian BA, Kimberly RP: End-stage kidney disease in African Americans with lupus nephritis associates with APOL1. Arthritis Rheumatol 66: 390–396, 2014
26. Kanji Z, Powe CE, Wenger JB, Huang C, Ankers E, Sullivan DA, Collerone G, Powe NR, Tonelli M, Bhan I, Bernhardy AJ, Dibartolo S, Friedman D, Genovese G, Pollak MR, Thadhani R: Genetic variation in APOL1 associates with younger age at hemodialysis initiation. J Am Soc Nephrol 22: 2091–2097, 2011
27. Tzur S, Rosset S, Skorecki K, Wasser WG: APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease. Nephrol Dial Transplant 27: 1498–1505, 2012
28. Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, Langefeld CD, Bowden DW, Hicks PJ, Stratta RJ, Lin JJ, Kiger DF, Gautreaux MD, Divers J, Freedman BI: The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 11: 1025–1030, 2011
29. Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR: Populationbased risk assessment ofAPOL1 on renal disease. J AmSocNephrol 22: 2098–2105, 2011
30. Freedman BI, Langefeld CD, Turner J, Nunez M, High KP, Spainhour M, Hicks PJ, Bowden DW, Reeves-Daniel AM, Murea M, Rocco MV, Divers J: Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patientswith non-diabetic end-stage renal disease. Kidney Int 82: 805–811, 2012
31. Foster MC, Coresh J, Fornage M, Astor BC, Grams M, Franceschini N, Boerwinkle E, Parekh RS, Kao WH: APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 24: 1484–1491, 2013
32. Palmer ND, Freedman BI: APOL1 and progression of nondiabetic nephropathy. J Am Soc Nephrol 24: 1344–1346, 2013
33. Freedman BI, Edberg JC, Comeau ME, Murea M, Bowden DW, Divers J, Alarcon GS, Brown EE, McGwin G Jr., Kopp JB, Winkler CA, Nelson GW, Illei G, Petri M, Ramsey-Goldman R, Reveille JD, Vila LM, Langefeld CD, Kimberly RP; PROFILE Study Group: The non-muscle Myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans. AmJ Nephrol 32: 66–72, 2010
34. Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr., Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ; AASK Study Investigators; CRIC Study Investigators: APOL1 risk variants, race, and progression of chronic kidney disease. NEngl J Med 369: 2183–2196, 2013
35. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS; Family Investigation of Nephropathy and Diabetes Research Group: MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40: 1185–1192, 2008
36. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40: 1175–1184, 2008
37. Freedman BI, Langefeld CD, Lu L, Divers J, Comeau ME, Kopp JB, Winkler CA, Nelson GW, Johnson RC, Palmer ND, Hicks PJ, Bostrom MA, Cooke JN, McDonough CW, Bowden DW: Differential effects of MYH9 and APOL1 risk variants on FRMD3 association with diabetic ESRD in African Americans. PLoS Genet 7: e1002150, 2011
38. Gopalakrishnan I, Iskandar SS, Daeihagh P, Divers J, Langefeld CD, Bowden DW, Hicks PJ, Rocco MV, Freedman BI: Coincident idiopathic focal segmental glomerulosclerosis collapsing variant and diabetic nephropathy in an African American homozygous for MYH9 risk variants. Hum Pathol 42: 291–294, 2011
39. Kroemer G, Marino G, Levine B: Autophagy and the integrated stress response. Mol Cell 40: 280–293, 2010
40. Wan G, Zhaorigetu S, Liu Z, Kaini R, Jiang Z, Hu CA: Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J Biol Chem283: 21540– 21549, 2008
41. Godel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, Debreczeni-Mor A, Lindenmeyer MT, Rastaldi MP, Hartleben G, Wiech T, Fornoni A, Nelson RG, Kretzler M, Wanke R, Pavenstadt H, Kerjaschki D, Cohen CD, Hall MN, Ruegg MA, Inoki K, Walz G, Huber TB: Role of mTOR in podocyte function and diabetic nephropathy in humans andmice. JClinInvest 121: 2197–2209, 2011
42. Kume S, Thomas MC, Koya D: Nutrient sensing, autophagy, and diabetic nephropathy. Diabetes 61: 23–29, 2012
43. Ulasi II, Tzur S, Wasser WG, Shemer R, Kruzel E, Feigin E, Ijoma CK, Onodugo OD, Okoye JU, Arodiwe EB, Ifebunandu NA, Chukwuka CJ, Onyedum CC, Ijoma UN, Nna E, Onuigbo M, Rosset S, Skorecki K: High population frequencies of APOL1 risk variants are associated with increased prevalence of nondiabetic chronic kidney disease in the Igbo people from southeastern Nigeria. Nephron Clin Pract 123: 123–128, 2013
44. Kopp JB: Rethinking hypertensive kidney disease: Arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder. Curr Opin Nephrol Hypertens 22: 266–272, 2013
45. Hays T, Wyatt CM: APOL1 variants in HIV-associated nephropathy: Just one piece of the puzzle. Kidney Int 82: 259–260, 2012
46. Kalayjian RC, Lau B, Mechekano RN, Crane HM, Rodriguez B, Salata RA, Krishnasami Z, Willig JH, Martin JN, Moore RD, Eron JJ, KitahataMM: Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care. AIDS 26: 1907–1915, 2012
47. Fine DM, Wasser WG, Estrella MM, Atta MG, Kuperman M, Shemer R, Rajasekaran A, Tzur S, Racusen LC, Skorecki K: APOL1 risk variants predict histopathology and progression to ESRDinHIVrelated kidney disease. J Am Soc Nephrol 23: 343–350, 2012
48. Estrella MM, Wyatt CM, Pearce CL, Li M, Shlipak MG, Aouizerat BE, Gustafson D, Cohen MH, Gange SJ, Kao WH, Parekh RS: Host APOL1 genotype is independently associated with proteinuria in HIV infection. Kidney Int 84: 834–840, 2013
49. Freedman BI, Spray BJ, Tuttle AB, Buckalew VM Jr.: The familial risk of end-stage renal disease in African Americans. Am J Kidney Dis 21: 387–393, 1993
50. Freedman BI, Iskandar SS, Appel RG: The link between hypertension and nephrosclerosis. AmJ KidneyDis 25: 207–221, 1995
51. Freedman BI, Murea M: Target organ damage in African American hypertension: Role of APOL1. Curr Hypertens Rep 14: 21–28, 2012
52. Skorecki KL, Wasser WG: Hypertension-misattributed kidney disease in African Americans. Kidney Int 83: 6–9, 2013
53. Ito K, Bick AG, Flannick J, Friedman DJ, Genovese G, Parfenov MG, Depalma SR, Gupta N, Gabriel SB, Taylor HA Jr., Fox ER, Newton-Cheh C, Kathiresan S, Hirschhorn JN, Altshuler DM, Pollak MR, Wilson JG, Seidman JG, Seidman C: Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res 114: 845–850, 2014
54. Rao TK, Filippone EJ, Nicastri AD, Landesman SH, Frank E, Chen CK, Friedman EA: Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 310: 669–673, 1984
55. Freedman BI, Wilson CH, Spray BJ, Tuttle AB, Olorenshaw IM, Kammer GM: Familial clustering of end-stage renal disease in blacks with lupus nephritis. Am J Kidney Dis 29: 729–732, 1997
56. Freedman BI, Soucie JM, Stone SM, Pegram S: Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 34: 254–258, 1999
57. Behar DM, Kedem E, Rosset S, Haileselassie Y, Tzur S, Kra-Oz Z, Wasser WG, Shenhar Y, Shahar E, Hassoun G, Maor C, Wolday D, Pollack S, Skorecki K: Absence of APOL1 risk variants protects against HIV-associated nephropathy in the Ethiopian population. Am J Nephrol 34: 452–459, 2011
58. Taylor HE, Khatua AK, Popik W: The innate immune factor apolipoprotein L1 restricts HIV-1 infection. J Virol 88: 592–603, 2014
59. Divers J, Nunez M, High KP, Murea M, Rocco MV, Ma L, Bowden DW, Hicks PJ, Spainhour M, Ornelles DA, Kleiboeker SB, Duncan K, Langefeld CD, Turner J, Freedman BI: JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy. Kidney Int 84: 1207–1213, 2013
60. Kopp JB: JC viruria and kidney disease in APOL1 risk genotype individuals: Is this a clue to a gene 3 environment interaction? Kidney Int 84: 1069–1072, 2013
61. Cheng XS, Bohl DL, Storch GA, Ryschkewitsch C, Gaudreault- Keener M, Major EO, Randhawa P, Hardinger KL, Brennan DC: Inhibitory interactions between BK and JC virus among kidney transplant recipients. J Am Soc Nephrol 22: 825–831, 2011
62. Pires EP, Bernardino-Vallinoto CV, Alves DM, Migone SR, Machado LF, Ishak MO, Ishak R, Cayres-Vallinoto IM, Vallinoto AC: Prevalence of infection by JC and BK polyomaviruses in kidney transplant recipients and patients with chronic renal disease. Transpl Infect Dis 13: 633–637, 2011
63. Rossi AP, Anderson KL, Brennan DC: JC polyoma virus and kidney disease. Kidney Int 85: 1242, 2014
64. Appel LJ, Wright JT Jr., Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X; AASK Collaborative Research Group: Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 363: 918–929, 2010
65. Genovese G, Tonna SJ, Knob AU, Appel GB, Katz A, Bernhardy AJ, Needham AW, Lazarus R, Pollak MR: A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containingAPOL1andMYH9. Kidney Int 78: 698–704, 2010
66. Bostrom MA, Kao WH, Li M, Abboud HE, Adler SG, Iyengar SK, Kimmel PL, Hanson RL, Nicholas SB, Rasooly RS, Sedor JR, Coresh J, Kohn OF, Leehey DJ, Thornley-Brown D, Bottinger EP, Lipkowitz MS, Meoni LA, Klag MJ, Lu L, Hicks PJ, Langefeld CD, Parekh RS, Bowden DW, Freedman BI; Family Investigation of Nephropathy and Diabetes (FIND) Research Group: Genetic association and gene-gene interaction analyses in African American dialysis patients with nondiabetic nephropathy. Am J Kidney Dis 59: 210–221, 2012
67. Divers J, Palmer ND, Lu L, Langefeld CD, Rocco MV, Hicks PJ, Murea M, Ma L, Bowden DW, Freedman BI: Gene-gene interactions in APOL1-associated nephropathy. Nephrol Dial Transplant 29: 587–594, 2014
68. Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MC, Niaudet P, Antignac C: NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 24: 349–354, 2000
69. Dusel JA, Burdon KP, Hicks PJ, Hawkins GA, Bowden DW, Freedman BI: Identification of podocin (NPHS2) gene mutations in African Americans with nondiabetic end-stage renal disease. Kidney Int 68: 256–262, 2005
70. Martini S, Nair V, Patel SR, Eichinger F, Nelson RG, Weil EJ, Pezzolesi MG, Krolewski AS, Randolph A, Keller BJ, Werner T, Kretzler M: From single nucleotide polymorphism to transcriptional mechanism: A model for FRMD3 in diabetic nephropathy. Diabetes 62: 2605–2612, 2013
71. Schaefer E, Zaloszyc A, Lauer J, Durand M, Stutzmann F, Perdomo-Trujillo Y, Redin C, Bennouna Greene V, Toutain A, Perrin L, Gerard M, Caillard S, Bei X, Lewis RA, Christmann D, Letsch J, Kribs M, Mutter C, Muller J, Stoetzel C, Fischbach M, Marion V, Katsanis N, Dollfus H: Mutations in SDCCAG8/ NPHP10 cause Bardet-Biedl syndrome and are associated with penetrant renal disease and absent polydactyly. Mol Syndromol 1: 273–281, 2011
72. Cadwell K, Patel KK, Maloney NS, Liu TC, Ng AC, Storer CE, Head RD, Xavier R, Stappenbeck TS, Virgin HW: Virusplus- susceptibility gene interaction determines Crohn’s disease gene Atg16L1 phenotypes in intestine. Cell 141: 1135–1145, 2010
73. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM: Finding the missing heritability of complex diseases. Nature 461: 747–753, 2009